ClinicalTrials.gg
CompletedNCT01206595Updated Jan 25, 2021Results posted

Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy

A Phase 2 interventional study of SKY0402 and Bupivacaine HCl in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
246th of 364
58 · median 70
Started
2005
with 1 other
Phase 2
43 of 364
4 open now
Registered
21st of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 246th largest by enrollment, is one of 2 that started in 2005, is one of 43 in phase 2, and was the 21st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study was to determine the appropriate dose of SKY0402 administered as a nerve block for the management of postoperative pain following bunionectomy.

Read the detailed description

This Phase 2, multicenter, randomized, double blind, dose escalating/de-escalating study evaluated the safety, efficacy, and pharmacokinetics of a single dose of SKY0402 compared to a single 125 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing bunionectomy.

Up to 88 subjects were to be randomized in five consecutive cohorts. The dose of bupivacaine HCl (125 mg) was to remain constant for all cohorts. After completion of Cohort 1, the decision to increase or decrease the dose of SKY0402 was made by a Cohort Data Review Committee following a review of pharmacokinetic, safety, and selected efficacy data from the previous cohort.

Study drug was to be administered as an ankle block, with or without a tourniquet, between 1 hour before the induction of general anesthesia and 20 minutes before the end of general anesthesia. The ankle block procedure consisted of five injections via three skin entries targeting the following nerves: posterior tibial, sural, deep peroneal, superficial peroneal, and saphenous.

The use of intravenous fentanyl during general anesthesia was permitted, but was not to exceed 250 micrograms. The intraoperative use of morphine was prohibited. Postoperatively, subjects had access to both opioid and non-opioid supplemental pain medication under general guidelines. Blood samples for the determination of plasma bupivacaine concentrations were obtained at Baseline and at specified time points through 96 hours.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Postoperative Pain
  • Bunionectomy
  • Analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were eligible for enrollment if they met the following criteria:

  1. Males and females ≥18 years of age at the Screening Visit. NOTE: Eligible females were or surgically sterile, or, if of child bearing potential, were not pregnant or nursing, and they agreed to not become pregnant during the study by using acceptable means of for at least 1 month before and 1 month after dosing, including any of the following: hormonal contraceptives (oral, injectable, implantable), effective barrier methods (e.g., condoms with spermicide), intrauterine device (IUD), lifestyle with a personal choice of abstinence, non-heterosexual lifestyle, or in a strictly monogamous relationship with a partner who has had a vasectomy.
  2. Scheduled to undergo a primary unilateral first metatarsal bunionectomy repair under general anesthesia, with or without internal fixation.

    NOTE: For the purpose of this protocol, all surgical procedures involving osteotomy of the first metatarsal (significant bone resection, excision, surgical fracture, etc.) or fusion of the first metatarsal phalangeal joint were considered qualified procedures, whether or not performed specifically to repair a bunion (hallus valgus deformity). Surgical techniques accompanied by minimal bone excision (e.g. cheilectomy) or procedures limited to soft tissue repair were not eligible for this study.

  3. American Society of Anesthesiology (ASA) Physical Class 1 or 2.
  4. Able and willing to comply with all study visits and procedures.
  5. Capable of speaking and understanding the local language sufficiently to provide responses to pain assessment scales.
  6. Willing and capable of providing written .

Exclusion criteria

Exclusion Criteria:

Subjects were excluded from the study if they met any of the following criteria:

  1. (ECG) abnormalities at Screening or on Day 1 (before dosing).
  2. Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.
  3. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, might have increased the risk of surgery or complicated the subject's postoperative course.
  4. Opioid medication usage during the 7 day period preceding the administration of study drug.
  5. Current medical conditions that could have required treatment with analgesic medications in the postoperative period for pain that was not surgically related (e.g., rheumatoid arthritis).
  6. >30 kg/m\^2.
  7. Body weight less than 60 kilograms.
  8. History of or idiosyncratic reaction to amide type local anesthetic agents.
  9. History of hypersensitivity, idiosyncratic reactions, and other to the pain control agents (opioid or non-opioid) anticipated to be used postoperatively. These contraindications may have included the following: angioedema and bronchospastic reactivity to non-steroidal anti-inflammatory drug (NSAID), peptic ulcer (active within the last 3 months), or hepatic or renal insufficiency.
  10. Coagulation disorders or ongoing anticoagulation treatment.
  11. Administration of an drug within 30 days or 5 half lives (of elimination), whichever was longer, prior to study drug administration.
  12. Suspected or known history of substance abuse and/or alcoholism.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Active comparator
    SKY0402

    Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)

    Drug: SKY0402

  • Active comparator
    Bupivacaine HCl

    Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402

    Drug: Bupivacaine HCl

Interventions

  • Single dose of SKY0402 administered as a nerve block

  • Single dose of 125 mg administered as a nerve block

06

What researchers measure

Primary outcomes

  1. Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain

    The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.

    Time frame: Through 96 hours postdose

Secondary outcomes

  1. Number of Patients With Adverse Events

    All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.

    Time frame: Through 30 days postdose

07

Results

Posted May 15, 2012

Participant flow

Participant flow — Overall Study
MilestoneSKY0402Bupivacaine HCl
Started3820
Completed3820
Not completed00

Outcome measures

PrimaryTime to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain

The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.

Time frame:
Through 96 hours postdose
Reported as:
Median · hours
Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain
hoursBupivacaine HClSKY0402 Low Dose (175 mg)SKY0402 Low-Mid Dose (225 mg)SKY0402 Mid Dose (350 mg)
Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain9.4 (6.1 to 11.2)1.9 (0.3 to 9.0)1.2 (0.6 to 5.4)2.4 (0.3 to 8.3)
SecondaryNumber of Patients With Adverse Events

All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.

Time frame:
Through 30 days postdose

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SKY0402—1/38 (2.6%)15/38 (39.5%)
Bupivacaine HCl—0/20 (0%)6/20 (30%)
Most frequent serious events
Most frequent serious events
EventSKY0402Bupivacaine HCl
Immobiliaztion prolongedInjury, poisoning and procedural complications1/380/20
Most frequent other events
Most frequent other events
EventSKY0402Bupivacaine HCl
NauseaGastrointestinal disorders9/383/20
HypotensionVascular disorders0/383/20
VomitingGastrointestinal disorders3/380/20
BradycardiaCardiac disorders2/380/20
ConstipationGastrointestinal disorders2/380/20
HeadacheNervous system disorders2/380/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SKY0402Bupivacaine HClTotal
<=18 years000
Between 18 and 65 years291544
>=65 years9514
Age, Continuous
Age, Continuous(years)SKY0402Bupivacaine HClTotal
Mean54.3 ± 14.0455.7 ± 14.2254.8 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)SKY0402Bupivacaine HClTotal
Female301848
Male8210
Region of Enrollment
Region of Enrollment(participants)SKY0402Bupivacaine HClTotal
Australia358
Belgium291241
United Kingdom325
Netherlands314
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Mar 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 6 years 2 months after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2010
First posted
Sep 22, 2010
Start
Mar 2005
Primary completionActual
Mar 2006
CompletionActual
Dec 2006
Results delay requested
Sep 22, 2010
Results first posted
May 15, 2012
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01206595
Responsible party
Sponsor
First posted
Sep 22, 2010
Start date
Mar 2005
Primary completion
Mar 2006
Completion
Dec 2006
Results posted
May 15, 2012
Last update
Jan 25, 2021

Study contacts

Kay Warnott, RN, ACNP
study director · Parica Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion